☰ Menu
× Close

Press Releases


Aug. 5 2020

Vyripharm International, Inc. and the National Yang-Ming University Signed a MOU to Develop VYR-206 as a Novel Diagnostic Approach for Neurological Disorders Outcomes Following Treatments

Jun. 15 2020

Vyripharm Biopharmaceuticals and Regis Technologies, Inc. Have Signed Off on a Master Drug Program Agreement for Expediting cGMP Manufacture of Our Antiviral Agents for Diagnostic Evaluation of COVID-19

Mar. 26 2020

Vyripharm Biopharmaceuticals Is in the Development Stage of a Novel Integrated Theranostic Approach for the Treatment of Viral Infections Such as COVID-19